Otros idiomas Rohto Pharmaceutical Co.,Ltd.

Acciones

4527

JP3982400008

Diferido Japan Exchange Otros sitios de cotización 07:01:36 01/05/2024			Varia. Cinco días.	Varia. 1 de enero.
3.088 ^JPY	+0,16 %		+3,49 %	+8,58 %

04/04	Mitsui y Rohto comprarán la empresa de medicinas chinas Eu Yan Sang por 594 millones de dólares	RE
2023	Las acciones japonesas cierran el lunes marginalmente al alza a la espera de la reunión Biden-Xi	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Rohto Pharmaceutical Eyes MGO on Singapore's Eu Yan Sang International for 88 Billion Yen	04/04
Rohto Pharmaceutical, Mitsui & Co. to Acquire Singapore-Based Eu Yan Sang -- Update	04/04
Mitsui and Rohto to buy $594 mln Chinese medicines company Eu Yan Sang	04/04
Rohto Pharmaceutical, Mitsui & Co. to Acquire Singapore-Based Eu Yan Sang	04/04
Rohto Pharmaceutical Co.,Ltd., Mitsui & Co., Ltd. and others agreed to acquire an 86% stake in Eu Yan Sang International Ltd from Blanca Investments Pte. Ltd., Tower Capital Asia and founding family for approximately SGD 690 million.	04/04
FiNC Technologies Co., Ltd. announced that it has received funding from Rohto Pharmaceutical Co.,Ltd.	28/03
Rohto Pharmaceutical's Profit Climbs 21% in Fiscal Nine Months, Lifts Fiscal-Year Outlook	12/02
Alina Vision Pte Ltd. announced that it has received funding from Fred Hollows Foundation, Rohto Pharmaceutical Co.,Ltd., TVM Capital Healthcare Partners	16/01
Plantex Co., Ltd. announced that it has received funding from Rohto Pharmaceutical Co.,Ltd., Dai-ichi Life Holdings, Inc., RealTechJapan LLC.	30/11
Rohto Pharmaceutical Co.,Ltd.(TSE:4527) added to S&P Japan Mid Cap 100	29/11
Japanese Shares Close Marginally Higher Monday Ahead of Biden-Xi Meeting	13/11
Rohto Pharmaceutical’s Attributable Profit Soars 25.8% in Fiscal H1 on Significant Profit Increases Across Categories	13/11
Rohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Full Year Ending March 31, 2024	10/11
Rohto Pharmaceutical Co.,Ltd. Declares Dividend for the Second Quarter of Fiscal Ending March 31, 2024, Payable on December 7, 2023	10/11
Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	10/11
Australis Scientific Pty Ltd. announced that it has received funding from Rohto Pharmaceutical Co.,Ltd.	25/10/23
Butterfly Pea Laboratory Co., Ltd. announced that it has received funding from Rohto Pharmaceutical Co.,Ltd. and other investors.	02/10/23
Rohto Pharmaceutical’s Attributable Profit Rises 30% in Fiscal Q1 due to Significant Sales Increase	25/08/23
Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	09/08/23
Rohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	09/08/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Titulares

Rohto Pharmaceutical Co.,Ltd. : El laboratorio campeón de venta libre

16 de marzo 2023 a las 12:28